Telcon

Humanigen Reports Second Quarter 2021 Financial Results

Retrieved on: 
星期四, 八月 12, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, CFO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, European Directorate for the Quality of Medicines & HealthCare, Holocene, European Medicines Agency, COVID, Achievement, EUA, Marketing, MD, COVID-19, MAA, COO, FDA, Patient, Telcon, CRP, Health, Nasdaq, MHRA, Review, Pharmaceutical industry

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today provided a corporate and regulatory update and reported financial results for the second quarter and six months ended June 30, 2021.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today provided a corporate and regulatory update and reported financial results for the second quarter and six months ended June 30, 2021.
  • Second Quarter and Recent Highlights:
    Submitted an application to the FDA for an EUA for lenzilumab for the treatment of patients hospitalized with COVID-19.
  • Second Quarter and Six Months Ended June 30, 2021 Financial Results
    Net loss for the three months ended June 30, 2021 was $70.8 million or $1.20 per share as compared to $24.0 million or $0.79 per share for the three months ended June 30, 2020.
  • For the third quarter of 2021 the company anticipates the R&D expense related to lenzilumab production will be same level as the second quarter of 2021.

Humanigen Executes Licensing Agreement for Lenzilumab™ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines

Retrieved on: 
星期二, 十一月 3, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Air traffic control, Telcon, Humanigen, Inc., KPM Tech Co., Ltd/Telcon RF Pharmaceutical, Inc.

Telcon is an affiliate of KPM Tech and both companies recently invested in the Humanigen June 2020 PIPE offering.

Key Points: 
  • Telcon is an affiliate of KPM Tech and both companies recently invested in the Humanigen June 2020 PIPE offering.
  • Lenzilumab has a significant part to play in the treatment of patients in the pandemic and beyond.
  • We are honored to be selected to develop and potentially launch lenzilumab in South Korea and the Philippines.
  • Telcon and KPM Tech will be responsible for gaining regulatory approval and subsequent commercialization of lenzilumab in its territories.

Emmaus Life Sciences Announces the Sale of its Telcon RF Pharmaceutical Inc. Shares

Retrieved on: 
星期三, 十月 14, 2020
Air traffic control, Telcon, Enderby's Wharf, Geography of London

The balance of the net sale proceeds will be used by Emmaus for working capital purposes.

Key Points: 
  • The balance of the net sale proceeds will be used by Emmaus for working capital purposes.
  • Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, stated, "We are grateful to Telcon for the mutually agreed sale of our shares.
  • The sale of our shares in Telcon is beneficial to both parties and will allow us both greater flexibility and resources to continue to grow our respective businesses."
  • About Telcon RF Pharmaceutical Inc.
    Telcon RF Pharmaceutical Inc. manufactures and distributes radio frequency equipment and produces connectors, cable assemblies, and other wireless communication equipment.